This paper examines the relationship between hyperuricemia and hypertension, investigating whether lowering serum uric acid (SUA) can reduce blood pressure in hyperuricemic, obese hypertensive patients. The review covers the pathophysiology of gout and monosodium urate (MSU) crystal deposition, the role of serum urate in vascular and cardiac disease, and methodologies used to assess endothelial function and left ventricular hypertrophy (LVH) regression. The paper also evaluates allopurinol as a urate-lowering therapy (ULT), discussing its effects on oxidative stress and antihypertensive outcomes. The authors conclude that while early evidence is promising, further research is needed to establish definitive treatment recommendations for this patient population.
Hypertension is a significant global public health concern. Worldwide, roughly one-quarter of the adult population has hypertension. Epidemiological and experimental studies suggest a link between hyperuricemia and hypertension. Hyperuricemia affects 30–45% of patients with untreated hypertension, while a much lower prevalence has been reported in normotensive individuals and the general population. As Hussar (2010, p. 70) notes, "whether lowering serum uric acid (SUA) may lower blood pressure is an unanswered question."
High serum urate concentration is an established causative factor in the development of gouty arthritis. There is growing interest in the role of serum urate as a contributing factor in the development or worsening of vascular, cardiac, and renal disease. The relationship between serum urate levels and blood pressure (BP) has been described for many years, and evidence from animal studies provides strong support for this association.
The contribution of serum urate to hypertension is further supported by evidence from small clinical trials demonstrating the antihypertensive benefit of urate-lowering therapy (ULT) in adolescents, through left ventricular hypertrophy (LVH) regression and improved vascular endothelial function. This research focuses on urate lowering in hyperuricemic, obese hypertensive patients, with the primary aim of investigating vascular endothelial function and LVH regression strategies.
This literature review documents an increase in the prevalence of both hyperuricemia and its occurrence in obese hypertensive patients over recent decades in developed nations. The association of hyperuricemia — and particularly of gout — with cardiovascular outcomes, and the potential benefits of early intervention, have recently been highlighted. The fact that crystal deposition and subclinical inflammation precede the clinical onset of gout may offer a new approach to treating hyperuricemia and gout.
Gout results from the nucleation and growth of monosodium urate (MSU) crystals in tissues in and around joints, following long-standing hyperuricemia — that is, serum urate above the saturation threshold. Hyperuricemia promotes MSU crystal deposits that are initially asymptomatic but can be detected by imaging techniques such as ultrasound and dual-energy computed tomography (DECT). Once formed, MSU crystals can cause acute, self-limited inflammatory flares, likely triggered by crystal shedding from the cartilage surface into the joint space, where they interact with resident cells.
If hyperuricemia persists, MSU crystal deposits further induce chronic inflammatory responses that may lead to damage of joint structures — the so-called chronic gouty arthritis, or chronic gout — which is typically associated with the presence of subcutaneous MSU deposits known as tophi. As deposits grow and comorbidities increase, gout becomes increasingly severe and difficult to treat, eventually becoming what is known as refractory gout.
Endothelial function testing (Flow-Mediated Dilation) and cardiac MR volumetric evaluation for left ventricular (LV) mass measurement were performed. Demographic data, clinical findings, laboratory results, body weight, and physical activity patterns were recorded. To determine endothelial function, acetylcholine endothelial function and adenosine coronary flow reserve tests were used to enhance a physician's capacity to identify and manage patients with endothelial dysfunction (Perez, 2009).
The drug adenosine, which normally causes the small vessels of the heart to dilate, was injected into one of the coronary arteries and the amount of blood flow was measured. Next, acetylcholine, which normally causes dilation of the large arteries, was injected and blood flow was again measured. If either test showed diminished blood flow to the heart muscle, a diagnosis of endothelial dysfunction and microvascular disease could be made. With evidence of insufficient blood flow to the heart muscle and open coronary arteries, restorative treatment could be directed at the specific problem (Sundy et al., 2011).
Endothelial dysfunction has been shown to be significant in predicting stroke and heart attacks, owing to the inability of blood vessels to dilate fully. These testing methods provided the foundational data for evaluating the effect of urate-lowering interventions on vascular function in the study population.
"Allopurinol dosing, antioxidant effects, and xanthine oxidase"
"Atherosclerosis risk and allopurinol clinical trial findings"
Khanna, D., Khanna, P. P., & Fitzgerald, J. D. (2012). American College of Rheumatology guidelines for management of gout: Therapy and anti-inflammatory prophylaxis of acute gouty arthritis, 64(10), 1447–1461.
Khanna, D., Khanna, P. P., & Hagerty, D. (2009). Patients that continue to flare despite apparent optimal urate lowering therapy.
Liu, X., Lewis, J. J., & Zhang, H. (2015). Effectiveness of electronic reminders to improve medication adherence in tuberculosis patients: A cluster-randomised trial, 12(9), 1–18.
Mantarro, S., Capogrosso, S. A., & Tuccori, M. (2015). Allopurinol adherence among patients with gout: An Italian general practice database study, 69(7), 757–765.
McGowan, B., Bennet, K., & Silke, C. (2016). Adherence and persistence to urate-lowering therapies in the Irish setting. Clinical Rheumatology, 35(3), 715–721.
Márquez, C. E., Martell, C. N., & Gil, G. V. (2006). Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: The EAPACUM-HTA Study, 24(1), 169–175.
Nasser, G. N., & Harrold, L. R. (2007). Overcoming adherence issues and other barriers to optimal care in gout. Current Opinion in Rheumatology, 27(2), 134–138.
Ogdie, A. R., Hoch, S., Dunham, J., & Von, J. M. (2010). A roadmap for education to improve the quality of care in gout. Current Opinion in Rheumatology, 22(2), 173–180.
Paulus, H. E., Schlosstein, L. H., Godfrey, R. G., Klinenberg, J. R., & Bluestone, R. (2004). Prophylactic colchicine therapy of intercritical gout: A placebo-controlled study of probenecid-treated patients, 17(5), 609–614.
Perez, R. F. (2009). Treating to target: A strategy to cure gout. Rheumatology (Oxford), 48(Suppl 2), ii9–ii14.
Saag, K. G., Fitz, F. D., & Kopicko, J. (2017). Lesinurad combined with allopurinol: A randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (a US-based study). Arthritis & Rheumatology, 69(1), 203–212.
Singh, J. A. (2014). Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: A qualitative study. Arthritis Research & Therapy, 16(2), R82.
Sundy, J. S., Baraf, H. B., & Yood, R. A. (2011). Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. JAMA, 306(7), 711–720.
Sarawate, C. A., Brewer, K. K., & Yang, W. (2006). Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clinic Proceedings, 81(7), 925–934.
Vaccher, S., Kannangara, D., & Baysari, M. (2016). Barriers to care in gout: From prescriber to patient, 43(1), 144–149.
Wortmann, R. L., Macdonald, P. A., Hunt, B., & Jackson, R. L. (2010). Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: Analysis of data from three phase III trials, (14), 2386–2397.
Wall, G. C., Koenigsfeld, C. F., Hegge, K. A., & Bottenberg, M. M. (2010). Adherence to treatment guidelines in two primary care populations with gout, 30(6), 749–753.
Wertheimer, A., Morlock, R., & Becker, M. A. (2013). A revised estimate of the burden of illness of gout. Current Therapeutic Research, 75, 1–4.
Yu, T., & Gutman, A. (2006). Efficacy of colchicine prophylaxis: Prevention of recurrent gouty arthritis over a mean period of 5 years in 208 gouty subjects. Annals of Internal Medicine, 55, 179–191.
You’re 59% through this paper. Sign up to read the remaining 2 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.